Answers are grounded in this paper and cite their sources.
To report pregnancy and infant outcomes among females with multiple sclerosis (MS) receiving ocrelizumab (OCR).
No takes yet. Share an insight, caveat, or question.
Bove et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: